No Data
No Data
Express News | Medicinova Chief Business Officer David H. Crean, Ph.d. Assumes Communications Role Overseeing Investor Engagement and Public Relations
Express News | Medicinova has received a new patent license notification for Mn-166 (ibudilast) for the prevention of various solid tumor metastases.
Express News | Medicinova Receives Notice of Allowance for New Patent Covering Mn-166 (Ibudilast) for the Prevention of Metastasis of Various Solid Cancer
MediciNova Presents New Data And Results Of Phase 1b/2a Clinical Trial Of MN-166 At ASCO Meeting
The highlights of presentation are as follows:The primary endpoints were safety and tolerability of MN-166 and TMZ combination treatment and the efficacy of combination treatment.The combination of Te
The combination of Tmz and Mn-166 is safe and well-tolerated, according to MediciNova company.
The combination of Tmz and Mn-166 is safe and well-tolerated, according to MediciNova company.
Medicinova announced at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting the phase 1B/2a clinical trial data of Mn-166 (ibudilast) for patients with glioblastoma in the United States.
Medicinova announced the phase 1B/2a clinical trial data of Mn-166 (ibudilast) for glioblastoma patients at the American Society of Clinical Oncology (ASCO) Annual Meeting in the United States in 2024.